Table 1. Patient Characteristics by Ketamine Treatment Group and Overall[a]

Characteristic	IV (n = 47)	IN (n = 15)	Total (N = 62)	P
Demographic				
Age, median (Q1, Q3) [min, max], y	50.6 (39.9, 54.3) [19.9, 63.8]	46.8 (37.3, 61.8) [26.5, 68.4]	50.2 (39.9, 55.5) [19.9, 68.4]	.39*
Sex, n (%)				.13[†]
Male	14 (29.8)	8 (53.3)	22 (35.5)	
Female	33 (70.2)	7 (46.7)	40 (64.5)	
Body mass index, median (Q1, Q3) [min, max]	27.9 (24.0, 32.4) [20.8, 39.6]	32.0 (27.7, 36.3) [23.8, 50.9]	28.5 (24.8, 33.4) [20.8, 50.9]	**.049***
Employment, n (%)				1.00[†]
Unemployed	3 (6.4)	0 (0.0)	3 (4.8)	
Employed	25 (53.2)	8 (53.3)	33 (53.2)	
Disability due to depression	11 (23.4)	4 (26.7)	15 (24.2)	
Homemaker, retired, or student	8 (17.0)	3 (20.0)	11 (17.7)	
Clinical				
Diagnosis, n (%)				1.00[†]
MDD	44 (93.6)	15 (100.0)	59 (95.2)	
BD-I	1 (2.1)	0 (0.0)	1 (1.6)	
BD-II	2 (4.3)	0 (0.0)	2 (3.2)	
Depression episode duration, median (Q1, Q3) [min, max], y	2.3 (1.0, 5.0) [0.3, 20.0]	8.0 (2.0, 11.0) [0.5, 37.0]	3.0 (1.5, 8.0) [0.3, 37.0]	**.01***
PTSD, n (%)	6 (12.8)	0 (0.0)	6 (9.7)	.32[†]
Anxiety disorders, n (%)	29 (61.7)	10 (66.7)	39 (62.9)	1.00[†]
Fibromyalgia or chronic pain, n (%)	4 (8.5)	3 (20.0)	7 (11.3)	.34[†]
OCD, n (%)	2 (4.3)	0 (0.0)	2 (3.2)	1.00[†]
Eating disorder, n (%)	2 (4.3)	1 (6.7)	3 (4.8)	1.00[†]
Borderline personality disorder, n (%)	3 (6.4)	2 (13.3)	5 (8.1)	.59[†]
History of substance use disorder, n (%)	4 (8.5)	4 (26.7)	8 (12.9)	.09[†]
Study Variables				
Esketamine nasal dosage deficit relative to IV ketamine dosage, median (Q1, Q3) [min, max], mg[b]	NA	8.4 (5.5, 24.2) [0.6, 24.8]	NA	NA
Baseline QIDS-SR score, median (Q1, Q3) [min, max]	17 (15, 20) [9, 24]	19 (18, 20) [16, 23]	18 (15, 20) [9, 24]	.07*
No. of treatments, n (%)				**<.001[†]**
1 to 3	25 (53.2)	1 (6.7)	26 (41.9)	
4 to 6	22 (46.8)	0 (0.0)	22 (35.5)	
7 or 8	0 (0.0)	14 (93.3)	14 (22.6)	
No. of treatments per week, median (Q1, Q3) [min, max][c]	1.5 (1.0, 2.0) [0.7, 3.0]	2.0 (1.6, 2.0) [0.7, 2.0]	1.5 (1.2, 2.0) [0.7, 3.0]	.11
QIDS-SR score change from baseline to last treatment, median (Q1, Q3) [min, max]	−8 (−13, −4) [−21, 3]	−10 (−13, −4) [−16, −2]	−8 (−13, −4) [−21, 3]	.84[†]
QIDS-SR score percent change from baseline to last treatment, median (Q1, Q3) [min, max]	−53 (−77, −25) [−100, 20]	−55 (−69, −24) [−80, −10]	−54 (−75, −24) [−100, 20]	.65[†]
Response, n (%)	27 (57.4)	9 (60.0)	36 (58.1)	1.00[†]
Remission, n (%)	20 (42.6)	4 (26.7)	24 (38.7)	.37[†]
Oxygen saturation[d]				
Change at 40 min[e]	0.44 (0.42)	−0.34 (0.52)	0.13 (0.33)	.25‡
Change to endpoint[f]	0.25 (0.44)	−0.30 (0.54)	0.03 (0.34)	.43‡
Systolic BP[d]				
Change at 40 min[e]	8.66 (1.25)	0.97 (1.35)	5.41 (1.09)	**<.001‡**
Change to endpoint[f]	5.88 (1.38)	1.02 (1.67)	3.94 (1.12)	**.03‡**
Diastolic BP[d]				
Change at 40 min[e]	3.38 (0.96)	2.27 (0.94)	2.82 (0.67)	.42‡
Change to endpoint[f]	1.30 (1.00)	2.53 (1.03)	1.90 (0.71)	.40‡
Heart rate[d]				
Change at 40 min[e]	1.66 (0.88)	−3.12 (1.05)	−0.24 (0.76)	**.001‡**
Change to endpoint[f]	0.42 (0.98)	−2.80 (1.22)	−0.84 (0.80)	**.04‡**
CADSS score[d]	4.14 (1.24)	8.09 (1.66)	5.53 (1.02)	.06‡
Current Medications				
No. of psychotropics, median (Q1, Q3) [min, max]	3.0 (3.0, 5.0) [1, 6]	3.0 (3.0, 5.0) [2, 7]	3.0 (3.0, 5.0) [1, 7]	.83*
Individual psychotropic/class, n (%)				
SSRI	12 (25.5)	4 (26.7)	16 (25.8)	1.00[†]
SNRI	16 (34.0)	5 (33.3)	21 (33.9)	1.00[†]
TCA	6 (12.8)	2 (13.3)	8 (12.9)	1.00[†]
MAOI	0 (0.0)	2 (13.3)	2 (3.2)	.056[†]
Atypical antipsychotics	17 (36.2)	3 (20.0)	20 (32.3)	.35[†]
Mirtazapine	4 (8.5)	1 (6.7)	5 (8.1)	1.00[†]
Bupropion	14 (29.8)	2 (13.3)	16 (25.8)	.31[†]
Stimulants	13 (27.7)	1 (6.7)	14 (22.6)	.16[†]
Trazodone	16 (34.0)	3 (20.0)	19 (30.6)	.36[†]
Gabapentin	6 (12.8)	1 (6.7)	7 (11.3)	1.00[†]
Z-drugs	6 (12.8)	5 (33.3)	11 (17.7)	.12[†]
Benzodiazepines	20 (42.6)	8 (53.3)	28 (45.2)	.56[†]
Neuromodulation (tried in current episode), n (%)				
ECT	17 (36.2)	2 (13.3)	19 (30.6)	.12[†]
TMS	8 (17.0)	2 (13.3)	10 (16.1)	1.00[†]

[a]Boldface indicates statistical significance.
[b]Deficit calculated from dosage esketamine nasal patient would have received during IV ketamine treatment minus 45% of their maximum esketamine dose.
[c]Patient-averaged number of treatments per week.
[d]n = 32 to 34 for IV patients because data were missing for 13 to 15 patients. n = 14 for IN patients for CADSS because data were missing for 1 patient. Values are shown as mean (SE).
[e]The value closest to 40 minutes after the start of treatment was used.
[f]The value at the end of the session within 100 minutes was used.
*Wilcoxon rank sum P value; [†]Fisher exact P value; ‡repeated-measures ANOVA.
Abbreviations: ANOVA = analysis of variance, BD = bipolar disorder, BMI = body mass index, BP = blood pressure, CADSS = Clinician-Administered Dissociative States Scale, ECT = electroconvulsive therapy, IN = intranasal, IV = intravenous, MAOI = monoamine oxidase inhibitor, MDD = major depressive disorder, NA = not applicable, OCD = obsessive-compulsive disorder, PTSD = posttraumatic stress disorder, QIDS-SR = 16-item Quick Inventory of Depressive Symptomatology self-report, SNRI = serotonin-norepinephrine reuptake inhibitor, SSRI = selective serotonin reuptake inhibitor, TCA = tricyclic antidepressant, TMS = transcranial magnetic stimulation.